Redx Pharma plc Redx presentations at AACR 2017

TIDMREDX

Redx Pharma plc

02 March 2017

2 March 2017

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

Redx to present new scientific data at AACR 2017

Redx, the drug development company, is pleased to announce that it will present two scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5, 2017, in Washington D.C., USA.

 
 Session Date        April 5, 2017, 8:00 AM -12:00 PM Eastern 
  & Time              Time 
------------------  ------------------------------------------------------------- 
 Session Title       Enzymes and Hormones and Metabolism 
                      in Tumor Immunity 
------------------  ------------------------------------------------------------- 
 Presentation        Development of 2(nd) generation indoleamine 
  Title               2,3-dioxygenase 1 (IDO1) selective 
                      inhibitors 
------------------  ------------------------------------------------------------- 
 Session Location    Section 24 
------------------  ------------------------------------------------------------- 
 Abstract #          5581 / 13 
------------------  ------------------------------------------------------------- 
 First author        Thomas Pesnot 
------------------  ------------------------------------------------------------- 
 Abstract online     http://www.abstractsonline.com/pp8/#!/4292/presentation/6237 
------------------  ------------------------------------------------------------- 
 
 
 Session Date        April 5, 2017, 8:00 AM -12:00 PM Eastern 
  & Time              Time 
------------------  ------------------------------------------------------------- 
 Session Title       Oncogenes and Tumor Suppressors as 
                      Therapeutic Targets 
------------------  ------------------------------------------------------------- 
 Presentation        Development of REDX05358, a novel 
  Title               highly selective and potent pan RAF 
                      inhibitor and a potential therapeutic 
                      for BRAF and RAS tumors 
------------------  ------------------------------------------------------------- 
 Session Location    Section 6 
------------------  ------------------------------------------------------------- 
 Abstract #          5160 / 3 
------------------  ------------------------------------------------------------- 
 First author        Helen Mason 
------------------  ------------------------------------------------------------- 
 Abstract online     http://www.abstractsonline.com/pp8/#!/4292/presentation/4116 
------------------  ------------------------------------------------------------- 
 

Dr Neil Murray, CEO of Redx, said:

"We're delighted to present new scientific data on two of our pre-clinical programs at the AACR meeting in April. As we are moving closer to the clinic with our most advanced programs, the Porcupine inhibitor RXC004 and the reversible BTK inhibitor RXC005, we continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'

For further information, please contact:

 
Redx Pharma Plc 
Neil Murray, Chief Executive                  T: +44 151 
                                                706 4747 
Karl Hård, Head of Investor Relations   T: +44 7491 
 &                                               651 406 
 Corporate Communications 
 
  Cantor Fitzgerald Europe (Nomad & Broker)    T: +44 20 
                                               7894 7000 
Phil Davies/ Michael Reynolds 
 

About Redx Pharma Plc

Company website: Redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGRGDXISGBGRD

(END) Dow Jones Newswires

March 02, 2017 02:50 ET (07:50 GMT)